Tuesday, January 19, 2010
Pharma Pipeline News: Preliminary results from Nektar Therapeutics' NKTR-102 Phase 2 study in platinum-resistant ovarian cancer
Note: conference reporting news item
Jan 19, 2009: I’m a Cancer Patient. Should I Ask About PARP Inhibitors? - Health Advice Deborah K. Armstrong
Q. I’m a Cancer Patient. Should I Ask About PARP Inhibitors?
By Deborah K. Armstrong, M.D.
pdf file - application/criteria
abstract: Safety and efficacy results of the advanced renal cell carcinoma Sorafenib expanded access program in North America
Note: while this is not specific to ovarian cancer knowing the side effects which patients experienced may be helpful
abstract: Clinicopathological features of 67 cases of endometriosis-associated epithelial ovarian carcinoma (China)
"CONCLUSION: Patients of endometriosis-associated epithelial ovarian carcinoma, especially patients with tumors arising from endometriosis, were found to be younger, having a significant lower stage and a better survival, and were mostly diagnosed with the subtype of clear-cell."
abstract: Understanding the support needs of patients accessing test results online. PHRs offer great promise, but support issues must be addressed to
Understanding the support needs of patients accessing test results online. PHRs offer great promise, but support issues must be addressed to ensure appropriate access.
CA-125; C-reactive protein (CRP); serum amyloid A (SAA); interleukin 6 (IL-6); and interleukin 8 (IL-8)
"CONCLUSIONS: The use of a panel of plasma biomarkers for the identification of women with ovarian cancer delivers a significant increase in diagnostic performance when compared to the performance of CA-125 alone."
Consistency of self-reported first-degree family history of cancer in a population-based study - Brazil
"The prevalence of cancer history in an FDR (first degree relative) was similar to previous reports in other populations. Consistency and reliability of the self-reported information was high, regardless of educational level."
Note: numerous different treatments are discussed
"In only 10% of cases was a living will involved -- and in fully 35% of cases, the physician did not know if there was a living will or not."
2010 full free access: The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian c
( highly technical )The prosurvival activity of ascites against TRAIL is associated with a shorter disease-free interval in patients with ovarian cancer